Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02006784
Other study ID # CISA 2013 TASK II
Secondary ID
Status Completed
Phase N/A
First received December 4, 2013
Last updated May 1, 2017
Start date September 2013
Est. completion date April 2017

Study information

Verified date May 2017
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an open label, pilot, observational, prospective study of the safety of inactivated influenza vaccine (IIV) in children with systemic lupus erythematosus (SLE) to be conducted during the 2013-2014 influenza season. The study will test conventional and novel biomarkers to assess disease flare and vaccine response and will also collect self-reported signs/symptoms in reactogenicity diaries during the 14 days after vaccination.


Description:

This is an open label, pilot, observational, prospective study of the safety of inactivated influenza vaccine (IIV) in children with systemic lupus erythematosus (SLE) to be conducted during the 2013-2014 influenza season.

Annual receipt of IIV is recommended for persons with SLE and is considered a standard of care medical practice. The study will test conventional and novel biomarkers to assess disease flare and vaccine response and will also collect self-reported signs/symptoms in reactogenicity diaries during the 14 days after vaccination.

Little is known about the immune responses to influenza and other vaccines in children and adolescents with autoimmune conditions, both in terms of immunogenicity as well as the potential for triggering or worsening of immune/autoimmune pathways. Patients with SLE often must take two or more immunosuppressive medications to control their illness. Thus, it is critically important to study vaccine safety and immunogenicity within the pediatric SLE population rather than extrapolate the limited data available from adult clinical studies. Newly diagnosed, untreated patients will be too sick to include in this study. After that, patients are on some immunosuppressive regimen for an extended period of time.

This project will inform the process for a subsequent larger multi-center study to assess IIV safety utilizing an established clinical research network in pediatric rheumatology, such as the Childhood Arthritis and Rheumatology Research Alliance (CARRA) or other venue.

The pilot study will enroll 30 children with mild to moderate SLE as defined by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) of <6. A SLEDAI score is an SLE Disease Activity Index which consists of 24 items made up of both clinical data and laboratory results. This score is assessed each time that a patient with SLE is seen in the clinic. It is anticipated that the subjects would be enrolled over 2 to 3 months prior to the influenza season, so as to immunize the SLE patients with IIV before they would be exposed to the circulating wild-type influenza virus. Patients will be followed for 3 months.

Thirty patients receiving one of two different treatment regimens that are standard-of-care regimes, "Prednisone + Hydroxychloroquine" or Prednisone+ Hydroxychloroquine + Mycophenolate Mofetil (MMF), will be observed. All subjects will receive US-licensed influenza vaccines as part of standard medical practice.

These two regimens were chosen because they represent customary care immunosuppressant medication regimens for persons with SLE. In addition, MMF in the second treatment arm has an inhibitory effect on plasma cell development, therefore allowing us to explore whether patients receiving this drug will have diminished antibody responses in response to vaccination.

Fifteen patients will already be receiving Prednisone + Hydroxychloroquine and 15 patients will already be receiving Prednisone+ Hydroxychloroquine + Mycophenolate Mofetil (MMF) as their routine care


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date April 2017
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria:

INCLUSION CRITERIA:

Subjects who meet the following criteria will be allowed to participate in the study:

1. Complete immunization history must be available at time of enrollment

2. Patients will be aged 8-18 years at time of enrollment

3. Patient will have stable disease activity (no changes in SLEDAI >2 points) during the 3 months preceding enrollment.

4. Patients can be enrolled as soon as the seasonal IIV is available and prior to the onset of influenza activity in the community. Generally this will be between September 2013-January2014. If feasible, enrollment will end in December 2013, which is usually before influenza circulates widely in the community.

Exclusion Criteria:

Subjects who meet the following criteria will not be allowed to participate in the study:

1. Females who are known to be pregnant or breastfeeding

2. Moderate to high SLE disease activity at enrollment (SLEDAI >6)

3. Oral temp =100F (=37.8) within 72 hours prior to vaccination

4. History of allergy to egg or egg products or history of allergic reaction to previous influenza vaccination or vaccine constituent

5. History of Guillain-Barré syndrome after previous immunizations

6. Unstable SLE disease activity during 3 months prior to enrollment (change in SLEDAI score >2)

7. Requirement for high-dose IV Solumedrol and/or Cytoxan pulse therapy during 6 months prior to study

8. Any condition that study site investigator deems would put patient at unacceptable risk of injury or render patient unable to meet requirements of the protocol.

9. Received pre-medication with analgesic or antipyretic agents in the 6 hours prior to first vaccination, or planned medication with analgesic or antipyretic in the week following first vaccination. This criterion should not preclude subjects receiving such medication if the need arises. However, pre-medication is to be discouraged.

10. Patient has received other inactivated vaccines within 14 days prior to administration of IIV.

11. Patient is scheduled to receive another routinely administered inactivated vaccine within 14 days after IIV.

12. Patient is currently participating in a study that involves and experimental agent (vaccine, drug, biologic, device, blood product, or medication), or expects to receive another experimental agent during participation in this study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Baylor Institute for Immunology Research Dallas Texas

Sponsors (4)

Lead Sponsor Collaborator
Vanderbilt University Baylor Research Institute, Centers for Disease Control and Prevention, Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the achievability of the pilot protocol Ability to recruit the entire sample cohort of 30 subjects during the pre-planned enrollment period.
Eighty percent of subjects complete all blood draws within the designated time frame
Adherence to protocol for blood collection, reaction assessment, clinic follow up, and laboratory analysis for 80% of the enrolled cohor
18 months
Secondary Lupus Flares To ascertain the ability to detect flares and associate the flare to vaccine
To correlate post-vaccine changes in blood biomarkers with the development of flares as assessed by SLEDAI and BILAG scores as well as self- and physician-assessed reactogenicity
90 days
Secondary To assess immunogenicity of IIV in children with autoimmunity on two different immunosuppressive regimens To ascertain the development of neutralizing and hemagglutination inhibition (HAI) antibody titers at baseline and at 28 days (+ 7 day)
To correlate changes in blood biomarkers with response to vaccine using immune profiling analysis.
90days
See also
  Status Clinical Trial Phase
Completed NCT04461158 - CCCR Lupus Patient Navigator Program N/A
Completed NCT01072734 - Auto-immunity in Lupus Patients After Influenza Vaccine Phase 2
Completed NCT03626311 - Omega-3 Replacement With Krill Oil in Disease Management of SLE N/A
Withdrawn NCT02779153 - Acthar SLE (Systemic Lupus Erythematosus) Phase 4
Completed NCT01992666 - GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus N/A
Completed NCT00779194 - Prospective Study of Rapamycin for the Treatment of SLE Phase 2
Recruiting NCT00582881 - Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Terminated NCT02811094 - LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse N/A
Recruiting NCT05458622 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol Phase 3
Recruiting NCT06144710 - SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus Phase 1
Completed NCT03031925 - Detection of Annexin A2 in Systemic Lupus Erythematosus N/A
Not yet recruiting NCT06420154 - The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases Early Phase 1
Recruiting NCT05859997 - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases N/A
Recruiting NCT02782039 - Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
Recruiting NCT05567198 - Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Recruiting NCT05747651 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
Recruiting NCT03030976 - A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) Phase 1
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT05724940 - Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
Recruiting NCT06032923 - Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus Phase 1/Phase 2